文献速递类风湿关节炎

托珠单抗对比泼尼松治疗已确诊类风湿关节炎(TOPIRA):研究者发起的随机临床试验

Tocilizumab vs prednisone in established rheumatoid arthritis patients (TOPIRA): an investigator-initiated randomized clinical trial.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

在已确诊且对csDMARDs应答不足的RA患者中,开放标签随机试验比较每日10mg泼尼松与每周皮下托珠单抗162mg(均联合稳定csDMARDs)的12个月达标治疗策略;托珠单抗在6-12个月CDAI改善上优于泼尼松,毒性及影像学进展无显著差异。

要点

  • 托珠单抗组6-12个月CDAI平均改善优于泼尼松组(平方根尺度均差-0.64,95%CI -1.18至-0.09)。
  • 治疗切换率托珠单抗组28% vs 泼尼松组52%。
  • GTI毒性(P=0.922)、托珠单抗相关不良事件(P=1.00)及影像学进展(P=0.376)均无显著差异。

核心结论

  • 托珠单抗对疾病活动的改善优于泼尼松。
  • 12个月内关节破坏进展无显著差异,不良事件无重大差异。

研究设计与样本

  • 研究者发起的开放标签随机试验,比较每日10mg泼尼松与每周皮下托珠单抗162mg(均联合稳定csDMARDs),采用12个月达标治疗策略,3个月应答不足时切换至另一组。

主要发现

  • 6-12个月CDAI(平方根尺度)平均差异为-0.64(95%CI -1.18至-0.09),托珠单抗优于泼尼松。
  • 治疗切换率:托珠单抗组28% vs 泼尼松组52%。
  • GTI毒性P=0.922,托珠单抗相关不良事件P=1.00,影像学进展P=0.376,均无显著差异。
  • 符合方案分析结果相似。

临床怎么用

  • 对csDMARDs应答不足的已确诊RA患者,托珠单抗在12个月达标治疗策略下对疾病活动的改善优于每日10mg泼尼松。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In rheumatoid arthritis (RA) patients with an insufficient response to conventional synthetic DMARDs (csDMARDs), both biologic DMARDs and low-to-moderate dose glucocorticoids are effective treatment options. However, direct comparative evidence on their relative effectiveness and safety is lacking. METHODS: This investigator-initiated, open-label, randomized trial compared 10 mg daily prednisone to weekly subcutaneous tocilizumab (TCZ, 162 mg), both added to stable csDMARD therapy, in a 12-month treat-to-target strategy. If treatment response was inadequate at 3 months, patients switched to the alternative arm. The primary end point was Clinical Disease Activity Index (CDAI) averaged over months 6-12. Secondary outcomes included the Glucocorticoid Toxicity Index (GTI), TCZ-related adverse events and radiographic progression. RESULTS: Sixty-five patients with established RA were included in the intention-to-treat population. TCZ was superior in reducing CDAI over months 6-12 (mean difference on square root scale: -0.64; 95% CI: -1.18 to -0.09). Treatment was switched in 28% (TCZ) and 52% (prednisone). No significant differences were observed in toxicity (GTI: P = 0.922; TCZ-related adverse events: P = 1.00) or in radiographic progression (P = 0.376). On-treatment analyses yielded similar results. CONCLUSION: TCZ led to greater improvement in disease activity than prednisone. There was no significant difference in joint damage progression over 12 months and there were no major differences in adverse events. CLINICAL TRIAL REGISTRATION: EudraCT Number: 2017-003037-28.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fadaei S, van der Leeuw MS, Linn-Rasker SP, et al. Tocilizumab vs prednisone in established rheumatoid arthritis patients (TOPIRA): an investigator-initiated randomized clinical trial. Rheumatology (Oxford). 2026. PMID: 41206922. doi:10.1093/rheumatology/keaf591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。